Atlas Trials

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

Clinical trial NCT06375707 · COMPLETED

Trial details

NCT number
NCT06375707
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Breast Cancer
Start date
2024-01-09
Primary completion
2026-05-30
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.